11-dehydrothromboxane B2 as a marker of acetylsalicylic acid resistance in patients with stable coronary artery disease
Open Access
- 30 August 2023
- journal article
- research article
- Published by Scientia Publishing House LTD in Juvenis scientia
- Vol. 9 (4) , 42-52
Abstract
Introduction. Acetylsalicylic acid (ASA, aspirin) resistance is the inability to reduce thromboxane A2 synthesis in platelets and inhibit platelets activation and aggregation while taking ASA. Assessment of urinary 11-dehydrothromboxane B2 (11-dhTxB2) levels is one of the methods to identify aspirin resistance. Our research aimed to investigate whether urinary 11-dhTxB2 levels and other clinical and laboratory parameters are associated with a history of major adverse cardiovascular events (MACE) including myocardial infarction and ischaemic stroke in aspirin-treated patients with stable coronary artery disease. Patients and methods. In a cross-sectional study we investigated 82 patients with stable coronary artery disease who took ASA at doses of 75–150 mg/day. We used the evaluation of the urinary 11-dhTxB2 levels standardized by creatinine as a method to identify aspirin resistance. Statistical analysis was performed using Mann-Whitney U-test, ROC-analysis and multivariable logistic regression. Results. The medians of urinary 11-dehydrothromboxane B2 level in patients with and without MACE were 587.8 (Q1-Q3 512.8–800.3) pg/mg creatinine and 438.3 (Q1–Q3 337.6–577.9) pg/mg creatinine, respectively (p=0.001). The threshold level of urinary 11-dhTxB2, which predicted a high risk of aspirin resistance, was 521.1 pg/mg creatinine, and in 36 (43.9 %) patients the concentration of the 11-dhTxB2 exceeded this level. The regression model characterising the dependence of the presence of a history of MACE was constructed. It included platelet count, urinary levels of 11-dhTxB2 and the presence of type 2 diabetes. Sensitivity and specificity of the model were 55 % and 88.9 %, respectively. Conclusions. The results of the study demonstrate that the antiplatelet effect of aspirin is weaker in stable coronary artery disease patients with a history of MACE than in those without a history of MACE.Keywords
This publication has 22 references indexed in Scilit:
- Residual thromboxane activity and oxidative stressCoronary Artery Disease, 2017
- Urinary 11-Dehydro-Thromboxane B 2 and Mortality in Patients With Stable Coronary Artery DiseaseThe American Journal of Cardiology, 2017
- Laboratory Aspirin Resistance and the Risk of Major Adverse Cardiovascular Events in Patients with Coronary Heart Disease on Confirmed Aspirin AdherenceJournal of Atherosclerosis and Thrombosis, 2014
- Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary interventionEuropean Heart Journal, 2013
- Aspirin and aspirin resistance in coronary artery diseaseCurrent Opinion in Pharmacology, 2013
- Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery diseaseAmerican Heart Journal, 2012
- Aspirin ResistanceThe Neurohospitalist, 2011
- Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic AcidCirculation, 2008
- Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysisBMJ, 2008
- Platelet Dysfunction in Type 2 DiabetesDiabetes Care, 2001